S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
Closing prices for crude oil, gold and other commodities
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
Closing prices for crude oil, gold and other commodities
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
Closing prices for crude oil, gold and other commodities
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
Closing prices for crude oil, gold and other commodities
You Can Follow BlackRock’s Market View for Your Money
NYSE:ENFN

Enfusion (ENFN) Stock Price, News & Analysis

$9.57
+0.04 (+0.42%)
(As of 04/12/2024 ET)
Today's Range
$9.32
$9.58
50-Day Range
$7.83
$9.66
52-Week Range
$7.37
$11.56
Volume
269,388 shs
Average Volume
394,369 shs
Market Capitalization
$1.23 billion
P/E Ratio
119.64
Dividend Yield
N/A
Price Target
$9.33

Enfusion MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.67 Rating Score
Upside/​Downside
2.5% Downside
$9.33 Price Target
Short Interest
Healthy
4.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.00mentions of Enfusion in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$1,179 Sold Last Quarter
Proj. Earnings Growth
142.86%
From $0.07 to $0.17 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.55 out of 5 stars

Computer And Technology Sector

1234th out of 1,800 stocks

Prepackaged Software Industry

424th out of 591 stocks

ENFN stock logo

About Enfusion Stock (NYSE:ENFN)

Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois.

ENFN Stock Price History

ENFN Stock News Headlines

1970’s computer coder issues shocking A.I. warning
Louis Navellier is stepping forward with an urgent warning about artificial intelligence. He says that right now, there's a radical new A.I. innovation happening behind the scenes...And it's going to blindside millions of Americans.
1970’s computer coder issues shocking A.I. warning
Louis Navellier is stepping forward with an urgent warning about artificial intelligence. He says that right now, there's a radical new A.I. innovation happening behind the scenes...And it's going to blindside millions of Americans.
Stifel Nicolaus Keeps Their Buy Rating on Enfusion (ENFN)
William Blair Reaffirms Their Buy Rating on Enfusion (ENFN)
Earnings Outlook For Enfusion
Goldman Sachs Downgrades Enfusion (ENFN)
See More Headlines
Receive ENFN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/12/2024
Today
4/12/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Prepackaged software
Sub-Industry
N/A
Fax
N/A
Employees
1,102
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.33
High Stock Price Target
$11.00
Low Stock Price Target
$8.00
Potential Upside/Downside
-2.5%
Consensus Rating
Reduce
Rating Score (0-4)
1.67
Research Coverage
6 Analysts

Profitability

Net Income
$6.03 million
Pretax Margin
6.58%

Debt

Sales & Book Value

Annual Sales
$174.54 million
Cash Flow
$0.14 per share
Book Value
$0.61 per share

Miscellaneous

Free Float
77,892,000
Market Cap
$1.23 billion
Optionable
Optionable
Beta
1.00
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Oleg Movchan (Age 49)
    CEO & Director
    Comp: $876.34k
  • Mr. Bradley Herring (Age 53)
    Chief Financial Officer
    Comp: $267.05k
  • Ms. Bronwen Bastone (Age 51)
    Chief People Officer
    Comp: $566.25k
  • Mr. Stephen Malherbe
    Managing Partner
  • Mr. Neal Pawar
    Chief Operating Officer
  • Ms. Valeria Gutowski (Age 42)
    Chief Accounting Officer
  • Mr. Daniel Groman (Age 35)
    Chief Technology Officer
  • Mr. Ignatius Tochukwu Njoku
    Head of Investor Relations
  • Matt Campobasso
    General Counsel
  • Mr. Joseph Defeo
    Global Head of Managed Services Production

ENFN Stock Analysis - Frequently Asked Questions

Should I buy or sell Enfusion stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enfusion in the last year. There are currently 3 sell ratings, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" ENFN shares.
View ENFN analyst ratings
or view top-rated stocks.

What is Enfusion's stock price target for 2024?

6 Wall Street research analysts have issued twelve-month target prices for Enfusion's shares. Their ENFN share price targets range from $8.00 to $11.00. On average, they anticipate the company's stock price to reach $9.33 in the next year. This suggests that the stock has a possible downside of 2.5%.
View analysts price targets for ENFN
or view top-rated stocks among Wall Street analysts.

How have ENFN shares performed in 2024?

Enfusion's stock was trading at $9.70 on January 1st, 2024. Since then, ENFN stock has decreased by 1.3% and is now trading at $9.57.
View the best growth stocks for 2024 here
.

Are investors shorting Enfusion?

Enfusion saw a decline in short interest in March. As of March 31st, there was short interest totaling 2,260,000 shares, a decline of 25.2% from the March 15th total of 3,020,000 shares. Based on an average trading volume of 409,100 shares, the days-to-cover ratio is presently 5.5 days. Currently, 4.9% of the shares of the stock are short sold.
View Enfusion's Short Interest
.

When is Enfusion's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ENFN earnings forecast
.

How were Enfusion's earnings last quarter?

Enfusion, Inc. (NYSE:ENFN) announced its quarterly earnings results on Tuesday, March, 12th. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.03 by $0.02. The business earned $46.49 million during the quarter, compared to analysts' expectations of $45.56 million. Enfusion had a trailing twelve-month return on equity of 10.30% and a net margin of 3.45%.

What guidance has Enfusion issued on next quarter's earnings?

Enfusion updated its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $200.0 million-$210.0 million, compared to the consensus revenue estimate of $202.3 million.

When did Enfusion IPO?

Enfusion (ENFN) raised $300 million in an initial public offering on Thursday, October 21st 2021. The company issued 18,750,000 shares at a price of $15.00-$17.00 per share.

How do I buy shares of Enfusion?

Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ENFN) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners